Added to YB: 2026-09-22
Pitch date: 2026-09-21
MDGL [neutral]
Madrigal Pharmaceuticals, Inc.
Author Info
No bio for this author
Company Info
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
Market Cap
$12.3B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-36.99
P/E
-37.39
EV/Sales
9.18
Sector
Biotechnology
Category
growth
$MDGL Sunday funday thoughts
MDGL (overview): Madrigal’s Rezdiffra may become a megablockbuster without shareholders capturing commensurate value: it reached $364M in Q2, is running near $1.3B TTM and surpassed 50,000 active patients, but Madrigal’s costly work building the MASH market may disproportionately benefit deeper-pocketed competitors. Novo and Roche can leverage larger commercial machines and established metabolic franchises, while widespread concurrent GLP-1 use suggests the combination era is already here and may leave Rezdiffra foundational beneath therapies owned by larger companies.
Read full article (2 min)